公开(公告)号：US20250049733A1

公开(公告)日：2025-02-13

申请号：US18721048

申请日：2022-12-16

Applicant: ALPARIS, S.A. DE C.V.

Inventor： Gustavo BARRANCO HERNÁNDEZ ,  Héctor SENOSIAIN ARROYO

IPC: A61K31/12 ,  A61K9/00 ,  A61K31/14 ,  A61K31/198 ,  A61K36/9066 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61P31/14

Abstract: The present invention relates to a pharmaceutical composition for nasal delivery comprising a co-amorphous compound of curcumin and arginine for use in the treatment of infectious respiratory diseases and airborne diseases such as the respiratory infection caused by SARS-CoV-2, influenza virus, respiratory syncytial virus and adenovirus, among others.

公开(公告)号：US20240424045A1

公开(公告)日：2024-12-26

申请号：US18566653

申请日：2023-01-10

Applicant: OmniActive Health Technologies Limited

Inventor： Muralidhara PADIGARU ,  Abhijeet MORDE ,  Manutosh ACHARYA ,  Sumit PATIL ,  Ninad PURANIK ,  Anup DESHPANDE ,  Munja BAKAN

IPC: A61K36/29 ,  A61K31/015 ,  A61K31/14 ,  A61K31/355 ,  A61K31/4525 ,  A61K45/06 ,  A61P25/28

Abstract: The present invention relates to an oral berberis extract composition and the process for the preparation of the composition of berberis extract as whole or its salts and/or in combination with berberine, jatrorrhizine, and columbamine or its salts with at least one pharmaceutically and/or nutraceutically accepted excipients for prevention, improvement, and maintenance of cognitive health to a subject in need thereof. Further encompassing to the oral berberis composition wherein the berberis extract is comprised of berberis extract as whole or its salts and/or in combination with berberine and/or its salt, and optionally jatrorrhizine, and columbamine or its salts in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms. A method of use of the berberis extract composition for prevention, improvement, and maintenance of cognitive health.

公开(公告)号：US12171866B2

公开(公告)日：2024-12-24

申请号：US17059916

申请日：2019-05-29

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： Laurent Jeannin ,  Julien Hecq

IPC: A61K9/10 ,  A23D7/005 ,  A23D7/01 ,  A23D7/06 ,  A23L33/00 ,  A23L33/11 ,  A23L33/12 ,  A23L33/125 ,  A23L33/175 ,  A61J1/10 ,  A61J1/20 ,  A61J3/00 ,  A61K9/00 ,  A61K9/107 ,  A61K31/14 ,  A61K31/202 ,  A61K31/232 ,  A61K31/661 ,  A61K31/685 ,  A61K33/12 ,  A61K36/05 ,  A61K47/10

Abstract: The present disclosure relates to parenteral nutritional formulations, including ready-to-use parenteral nutrition formulations. More particularly, the present disclosure is directed to lipid formulations or emulsions and multi-chamber containers comprising same, wherein the lipid emulsion contains glycerophosphorylcholine as a choline source. The present disclosure further relates to methods of providing choline to a patient in need of parenteral nutrition and methods of avoiding and/or treating choline deficiency and liver damage.

公开(公告)号：US12171853B2

公开(公告)日：2024-12-24

申请号：US17465546

申请日：2021-09-02

Applicant: Innovative BioDefense, Inc.

Inventor： Jesse Cozean ,  Colette Cozean ,  Susan Goldsberry

IPC: A61K31/045 ,  A61K8/31 ,  A61K8/34 ,  A61K8/41 ,  A61K8/43 ,  A61K8/49 ,  A61K8/67 ,  A61K31/14 ,  A61K31/155 ,  A61K31/355 ,  A61K31/717 ,  A61K31/785 ,  A61K33/30 ,  A61K36/61 ,  A61K45/06 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/10

Abstract: Several embodiments disclosed herein relate to formulations having antimicrobial and/or sanitizing effects, and uses of the same. In particular, the formulations and methods of using same provide, in several embodiments, an immediate and a persistent antimicrobial effect against a broad spectrum of microorganisms.

公开(公告)号：US12161689B2

公开(公告)日：2024-12-10

申请号：US18059718

申请日：2022-11-29

Applicant: NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION

Inventor： Snezna Rogelj ,  Danielle Nicole Turner

IPC: A61K31/14 ,  A61K31/198 ,  A61K38/12 ,  A61K47/18 ,  A61K47/44 ,  A61P31/04 ,  A61P31/10

Abstract: The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

公开(公告)号：US20240358740A1

公开(公告)日：2024-10-31

申请号：US18766747

申请日：2024-07-09

Applicant: William H. Cross, III

Inventor： William H. Cross, III

IPC: A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

CPC classification number: A61K31/714 ,  A61K31/14 ,  A61K31/185 ,  A61K31/198 ,  A61K31/519 ,  A61P25/02

Abstract: The invention provides compositions and methods to treat diabetic neuropathies. In particular the invention has discovered that, in combination with a folic compound, particular combinations of two types of additional antioxidants have complementary effects for use against diabetic neuropathies. These include antioxidants that comprise stabilizing heteroatoms and antioxidants with an extended conjugated segment, where at least one of the antioxidants that comprises a stabilizing heteroatom also has pro-oxidant effects.

公开(公告)号：US12128120B2

公开(公告)日：2024-10-29

申请号：US18217568

申请日：2023-07-02

Applicant: Next Science IP Holdings Pty Ltd

Inventor： Matthew F. Myntti

IPC: A61K8/49 ,  A01N25/02 ,  A01N25/08 ,  A01N25/30 ,  A01N37/36 ,  A01N41/04 ,  A01N59/00 ,  A01N59/26 ,  A01N61/00 ,  A61K8/19 ,  A61K8/34 ,  A61K8/365 ,  A61K8/37 ,  A61K8/39 ,  A61K8/41 ,  A61K8/44 ,  A61K8/46 ,  A61K8/55 ,  A61K8/60 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K31/14 ,  A61K31/19 ,  A61K31/194 ,  A61K33/00 ,  A61K33/02 ,  A61K33/04 ,  A61K33/20 ,  A61K33/24 ,  A61K33/32 ,  A61K33/42 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34 ,  A61L26/00 ,  A61P17/02 ,  A61P31/04 ,  A61Q11/00 ,  A61Q17/00 ,  A61K9/08

CPC classification number: A61K8/498 ,  A01N25/02 ,  A01N25/08 ,  A01N25/30 ,  A01N37/36 ,  A01N41/04 ,  A01N59/00 ,  A01N59/26 ,  A01N61/00 ,  A61K8/19 ,  A61K8/34 ,  A61K8/347 ,  A61K8/365 ,  A61K8/37 ,  A61K8/39 ,  A61K8/41 ,  A61K8/416 ,  A61K8/44 ,  A61K8/463 ,  A61K8/466 ,  A61K8/4926 ,  A61K8/4973 ,  A61K8/55 ,  A61K8/602 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/0063 ,  A61K9/06 ,  A61K31/14 ,  A61K31/19 ,  A61K31/194 ,  A61K33/00 ,  A61K33/02 ,  A61K33/04 ,  A61K33/20 ,  A61K33/24 ,  A61K33/32 ,  A61K33/42 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34 ,  A61L26/0066 ,  A61P17/02 ,  A61P31/04 ,  A61Q11/00 ,  A61Q17/005 ,  A61K9/08 ,  A61L2300/404 ,  A01N37/36 ,  A01N59/26 ,  A01N2300/00 ,  A01N25/02 ,  A01N25/30 ,  A01N59/00 ,  A01N61/00 ,  A01N25/08 ,  A01N25/30 ,  A01N59/00 ,  A01N61/00

Abstract: An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.

公开(公告)号：US20240349771A1

公开(公告)日：2024-10-24

申请号：US18637077

申请日：2024-04-16

Applicant: SOCIETE DES PRODUITS NESTLE S.A.

Inventor： Nora Schneider ,  Jonas Hauser ,  Sean Deoni ,  Tamas Bartfai ,  Jonathan O'Regan

IPC: A23L33/00 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A24B15/38 ,  A61K9/00 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28

CPC classification number: A23L33/40 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A24B15/38 ,  A61K9/0095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1564 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1618 ,  A23V2250/1642 ,  A23V2250/1846 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1862 ,  A23V2250/1886 ,  A23V2250/5424 ,  A23V2250/7056 ,  A23V2250/706

Abstract: A synthetic nutritional composition containing a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

公开(公告)号：US20240325324A1

公开(公告)日：2024-10-03

申请号：US18738665

申请日：2024-06-10

Applicant: Diana Driscoll

Inventor： Diana Driscoll

IPC: A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/381 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61K36/9066 ,  A61P27/04 ,  G01N33/569

CPC classification number: A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/375 ,  A61K31/381 ,  A61K31/4748 ,  A61K31/51 ,  A61K33/06 ,  A61K36/9066 ,  A61P27/04 ,  G01N33/56972 ,  G01N2800/16 ,  G01N2800/52

Abstract: The present invention includes compositions and methods for the treatment or prevention of a disease or condition that causes dry eyes comprising: an effective amount of at least two active agents selected from: (1) at least one cholinesterase inhibitor; (2) at least one form of choline; (3) at least one form of carnitine; (4) at least one form of muscarinic agonist, sufficient to treat the disease or condition that causes dry eyes.

公开(公告)号：US20240325323A1

公开(公告)日：2024-10-03

申请号：US18444485

申请日：2024-02-16

Applicant: i2O Therapeutics, Inc.

Inventor： Tyler BROWN ,  Kelly IBSEN

IPC: A61K31/14 ,  A61K38/00 ,  C07K14/575

CPC classification number: A61K31/14 ,  C07K14/575 ,  A61K38/00

Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.